Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
|Articles|April 1, 2013
The Journal of Targeted Therapies in Cancer
- April 2013
- Volume 1
- Issue 6
Full Version of the April 2013 Issue
Full Version of The International Journal of Targeted Therapies in Cancer from April 2013
Advertisement
The International Journal of Targeted Therapies in Canceris focused on the use of targeted therapies and personalized medicineone of the most rapidly growing and clinically challenging areas of oncology today.
This issue contains articles on:
- PI3K Inhibitors in Breast Cancer Treatment
- Cabozantinib in Medullary Thyroid Cancer
- Modulating the Immune System to Treat Non-Small Cell Lung Cancer
Advertisement
Related to this article
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Published findings from the ASPEN-06 trial of evorpacept in previously treated HER2+ gastric cancers included exploratory analyses suggesting CD47 is a predictive biomarker for benefit with the targeted agent.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
2
Proton Therapy Does Not Improve Survival in Advanced HCC Trial
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
CD47-Targeted Evorpacept Shows Durable Responses in HER2+ Gastric Cancer
5